摘要
ETS-1(E26transformation specific-1)可以上调U-PA(urokinase-type plasminogen activator)的表达,但两者相关性的大小尚不清楚.通过采用免疫组化和RT-PCR(reverse transcriptase polymerase chain reaction)检测非小细胞肺癌(non-small cell lung cancer,NSCLC)和癌旁正常组织中ETS-1和U-PA的表达.免疫组化结果显示,50例NSCLC组织中,ETS-1和U-PA蛋白阳性率分别为70%(35/50)和64%(32/50),均显著高于对应的癌旁正常组织15%(3/20)和10%(2/20)(P<0.001).ETS-1阳性率随着肿瘤侵润深度的增加,淋巴结转移和临床分期的增加而增加(P<0.05).U-PA阳性率随着淋巴结转移和临床分期的增加而增加(P<0.05).ETS-1和U-PA蛋白表达呈正相关(r=0.059,P<0.01).在17例癌组中和癌旁组中,ETS-1、U-PA mRNA的相对表达强度分别为(0.564±0.059)和(0.318±0.089)(P=0.000)、(0.773±0.191)和(0.401±0.193)(P=0.000).结果表明,ETS-1和U-PA的过量表达与NSCLC的发展密切相关,两者的表达呈正相关,ETS-1可能通过上调U-PA的表达,促进肺癌的进展.
U-PA expression can be up-regulated by ETS-1,but the value of their relationship was not clear.The expression of ETS-1and U-PA in non-small cell lung cancer(NSCLC)and normal tissues were detected by immunohistochemistry and RT-PCR.Immunohistochemical staining showed that the expression rate of ETS-1 and U-PA protein in NSCLC tissue were 70%(35 /50) and 64%(32 /50),which is significantly higher than that in the normal tissues,15%(3 /20)and 10%(2 /20)(P 0.001),respectively.The expression rate of ETS-1 protein was increased in deeper of invasion,lymph node metastasis and higher clinical stages (P 0.05)of NSCLC.The expression rate of U-PA protein was increased in lymph node metastasis and higher clinical stages(P0.05)of NSCLC.A positive correlation between the expression of ETS-1 and U-PA protein was found(r=0.509,P0.01).The relative expression intensity of ETS-1and U-PA mRNA in 17 NSCLC tissues were(0.564 ± 0.059)and(0.773 ± 0.191),significantly higher than that in corresponding normal tissues((0.318±0.089)(P=0.000),and(0.401±0.193)(P=0.000)).The results indicated that the progression of NSCLC was correlated closely with over-expression of ETS-1 and U-PA.There was a positive correlation between the expression of ETS-1 and U-PA protein.ETS-1 might be involved in progression of NSCLC via up-regulating the expression of U-PA.
出处
《生命科学研究》
CAS
CSCD
2010年第5期436-441,共6页
Life Science Research
基金
国家自然科学基金资助项目(30871137)